Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International Inc (VRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 7
List of Figures 9
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD 2018 15
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deal Details 24
Asset Purchase 24
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 24
Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 25
Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 27
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 28
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 29
Valeant Pharma Acquires Pharma Brands from Probiotec 30
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 32
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 33
Valeant Pharma Acquires US Rights To Targretin From Eisai 34
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 35
Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 36
Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 37
Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 38
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 39
Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 40
Venture Financing 41
Precision Dermatology Raises Additional US$26 Million In Venture Financing 41
Private Equity 42
Pacific Equity and Carlyle Acquires iNova Pharma from Valeant Pharma for USD930 Million 42
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 44
Partnerships 45
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 45
Namtall Enters into Licensing Agreement with Valeant Pharma 47
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 48
US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 49
Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 50
Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 51
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 52
Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 53
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 54
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 55
Lupin Enters into Distribution Agreement with Salix Pharma 56
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 57
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 58
Valeant Pharmaceuticals International Partners With Living Proof 59
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 60
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 61
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 62
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 63
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 64
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 65
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 66
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 67
Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 68
Licensing Agreements 69
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 69
Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 70
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 71
Valeant Pharma Amends Licensing Agreement with AstraZeneca 72
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 73
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 74
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 75
Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 76
Sirona Biochem Expands Licensing Agreement with Valeant Pharma 77
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 78
Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC-849 79
Valeant Pharma Enters into Licensing Agreement with SMG Pharma 80
Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 81
Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 82
Valeant Pharma Enters into Licensing Agreement with Norgine 83
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 84
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 85
Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 86
Equity Offering 87
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 87
Atlantic Healthcare Raises USD24 million in Private Placement of Shares 88
Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 89
Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 91
Bausch & Lomb Withdraws IPO 93
Debt Offering 95
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 95
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 96
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 97
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 98
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 99
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 100
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 101
Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due 2023 102
Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due 2023 103
Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due 2020 104
Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due 2025 105
Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due 2023 106
Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds 107
Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 108
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 109
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 110
Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 111
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 112
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 113
Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 114
Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 116
Asset Transactions 117
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 117
Valeant Pharma Receives Unsolicited Bids for its Core Assets 119
Valeant Pharma May Sell its Dermatology and Cancer Drugs 120
Valeant Pharma Plans to Sell Neuro Business 121
IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 122
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 123
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 124
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 125
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 127
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 128
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 129
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 130
Acquisition 131
Valeant Pharma Sells Sprout Pharma 131
Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 132
Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 133
Pershing Square Capital Management Sells its Investment in Valeant Pharma 134
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 135
Valeant Pharma May Sell Amoun Pharma 136
Valeant Pharma to Acquire Mercury (Cayman) 137
Valeant Pharma Acquires Sprout Pharma 139
Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 141
Valeant Pharma Acquires Nicox for USD20 Million 144
Valeant Canada Acquires CROMA Pharma Canada 145
Valeant Pharma Completes Acquisition of PreCision Dermatology 146
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 148
Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 149
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 151
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 153
Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 154
Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 156
Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 157
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 158
Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 160
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 162
Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 163
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 164
Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 166
Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 168
Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 169
Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 170
Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 171
Valeant Pharmaceuticals International Inc - Key Competitors 172
Valeant Pharmaceuticals International Inc - Key Employees 173
Valeant Pharmaceuticals International Inc - Locations And Subsidiaries 174
Head Office 174
Other Locations & Subsidiaries 174
Recent Developments 182
Financial Announcements 182
May 08, 2018: Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance 182
Feb 28, 2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results 185
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 189
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 191
May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 194
Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 195
Corporate Communications 199
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 199
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 200
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 201
Legal and Regulatory 202
May 15, 2018: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors 202
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 203
Other Significant Developments 204
May 08, 2018: Valeant Will Become Bausch Health Companies 204
Feb 27, 2017: Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity 205
Appendix 206
Methodology 206
About GlobalData 206
Contact Us 206
Disclaimer 206

List Of Tables

List of Tables
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Valeant Pharmaceuticals International Inc, Deals By Therapy Area, 2012 to YTD 2018 13
Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD 2018 15
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 24
Valeant Pharma Acquires Certain Assets of Dendreon for USD495 Million 25
Valeant Pharma Acquires Non-Strategic Products from Marathon Pharma 27
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 28
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 29
Valeant Pharma Acquires Pharma Brands from Probiotec 30
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 32
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 33
Valeant Pharma Acquires US Rights To Targretin From Eisai 34
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 35
Valeant Pharma Completes Acquisition Of Certain Assets From Swiss Herbal Remedies For US$21 Million 36
Valeant Pharma Completes Acquisition Of AcneFree And Certain Assets From University Medical For Up To US$105 Million 37
Valeant Pharma Completes Acquisition Of Certain Assets From Atlantis Pharma For Up To US$74 Million 38
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 39
Valeant Pharma Completes Acquisition Of Branded Generic Products Portfolio From Gerot Lannach For Up To US$184 Million 40
Precision Dermatology Raises Additional US$26 Million In Venture Financing 41
Pacific Equity and Carlyle Acquires iNova Pharma from Valeant Pharma for USD930 Million 42
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 44
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 45
Namtall Enters into Licensing Agreement with Valeant Pharma 47
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 48
US WorldMeds and Salix Pharma Enter into Co-Promotion Agreement 49
Egalet Enters into Co-Promotion Agreement with OraPharma for SPRIX Nasal Spray 50
Obagi Medical Products Enters into Distribution Agreement with Nextcell Medical 51
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 52
Orexigen Therapeutics Enters Into Distribution Agreement With Valeant For Contrave 53
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 54
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 55
Lupin Enters into Distribution Agreement with Salix Pharma 56
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 57
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 58
Valeant Pharmaceuticals International Partners With Living Proof 59
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 60
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 61
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 62
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 63
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 64
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 65
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 66
Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 67
Bausch & Lomb Japan Enters Into Co-Marketing Agreement With Wakamoto Pharma 68
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 69
Glycyx Pharma to Enter into Licensing Agreement with Valeant Pharma 70
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 71
Valeant Pharma Amends Licensing Agreement with AstraZeneca 72
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 73
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 74
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 75
Nicox Exercises Option Agreement with Bausch & Lomb to Co-Promote Latanoprostene Bunod 76
Sirona Biochem Expands Licensing Agreement with Valeant Pharma 77
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 78
Sirona Biochem Enters Into Licensing Agreement With Obagi Medical For TFC-849 79
Valeant Pharma Enters into Licensing Agreement with SMG Pharma 80
Medicis Pharma Enters Into Licensing Agreement With Specialty Pharma Company 81
Medicis Pharma Enters Into Licensing Agreement With 3M For Immune Response Modifiers 82
Valeant Pharma Enters into Licensing Agreement with Norgine 83
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 84
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 85
Bausch & Lomb Enters Into Licensing Agreement With Eye Therapies For Technology To Treat Ocular Redness 86
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 87
Atlantic Healthcare Raises USD24 million in Private Placement of Shares 88
Valeant Pharma Raises USD1162 Million in Public Offering of Common Stock 89
Valeant Pharma Completes Public Offering Of Shares For US$2.3 Billion 91
Bausch & Lomb Withdraws IPO 93
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 95
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 96
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 97
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 98
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 99
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 100
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 101
Valeant Pharma Raises USD3.25 Billion in Private Placement of 5.875% Notes Due 2023 102
Valeant Pharma Raises USD1.58 Billion in Private Placement of 4.5% Notes Due 2023 103
Valeant Pharma Raises USD2 Billion in Private Placement of 5.375% Notes Due 2020 104
Valeant Pharma Raises USD3.25 Billion in Private Placement of 6.125% Notes Due 2025 105
Valeant Pharma Raises USD1 Billion in Private Placement of 5.5% Senior Notes Due 2023 106
Valeant Pharma to Raises USD8.8 Billion in Public Offering of Bonds 107
Valeant Pharma to Raises USD2.5 Billion in Public Offering of Notes 108
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$900 Million 109
Valeant Pharma Completes Private Placement Of Notes Due 2021 For US$1.62 Billion 110
Valeant Pharma Completes Private Placement Of Notes Due 2018 For US$1.6 Billion 111
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 112
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 113
Medicis Pharma Completes Public Offering Of Convertible Senior Notes Due 2017 For US$500 Million 114
Salix Pharma Completes Private Placement Of 1.5% Convertible Senior Notes Due 2019 For US$690 Million 116
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 117
Valeant Pharma Receives Unsolicited Bids for its Core Assets 119
Valeant Pharma May Sell its Dermatology and Cancer Drugs 120
Valeant Pharma Plans to Sell Neuro Business 121
IGI Labs Acquires Two Ophthalmic Drug Products from Valeant Pharma for USD1.5 Million 122
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 123
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 124
Hyperion Therapeutics Completes Acquisition Of Rights To Buphenyl And Ammonul From Ucyclyd Pharma For US$51 Million 125
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 127
PreCision Dermatology Acquires Dermatology Products From Triax Pharma 128
Hyperion Therapeutics Acquires Rights Of Ravicti From Ucyclyd Pharma 129
Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 130
Valeant Pharma Sells Sprout Pharma 131
Haitong International Zhonghua Finance Acquires Obagi Medical Products from Valeant Pharma for USD190 Million 132
Sanpower Acquires Dendreon Pharma from Valeant Pharma for USD820 Million 133
Pershing Square Capital Management Sells its Investment in Valeant Pharma 134
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 135
Valeant Pharma May Sell Amoun Pharma 136
Valeant Pharma to Acquire Mercury (Cayman) 137
Valeant Pharma Acquires Sprout Pharma 139
Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 141
Valeant Pharma Acquires Nicox for USD20 Million 144
Valeant Canada Acquires CROMA Pharma Canada 145
Valeant Pharma Completes Acquisition of PreCision Dermatology 146
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 148
Salix Pharma Completes Acquisition Of Santarus For US$2.6 Billion In Tender Offer 149
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 151
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 153
Valeant Pharma International Completes Acquisition Of Obagi Medical Products For US$418 Million 154
Jelfa Pharm Sells Sanitas Pharma, Provider Of Marketing, Pharmacovigilance And Registration Services 156
Valeant Pharma Completes Acquisition Of Natur Produkt International For Up To US$185 Million 157
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 158
Valeant Pharma Completes Acquisition Of Medicis Pharma For US$2.6 Billion 160
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 162
Valeant Pharma To Acquire Silvanols, Pharmaceutical Manufacturer 163
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 164
Bausch & Lomb Completes Acquisition Of ISTA Pharma For US$500 Million 166
Valeant Pharma Acquires Pedinol Pharmacal, Provider Of Podiatric Medicine 168
Valeant Pharma International Completes Acquisition Of Eyetech For Up To US$26 Million 169
Valeant Pharma International Acquires 19.9% Stake In PeleNova Biotecnologia For US$10 Million 170
Valeant Pharma Acquires Sports Nutrition Products Company, Probiotica Laboratorios, For US$86 Million 171
Valeant Pharmaceuticals International Inc, Key Competitors 172
Valeant Pharmaceuticals International Inc, Key Employees 173
Valeant Pharmaceuticals International Inc, Other Locations 174
Valeant Pharmaceuticals International Inc, Subsidiaries 174

List Of Figures

List of Figures
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Valeant Pharmaceuticals International Inc, Medical Devices Deals, 2012 to YTD 2018 15

Valeant Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Valeant Pharmaceuticals International, Inc. - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Valeant Pharmaceuticals International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Valeant Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Valeant Pharmaceuticals International, Inc. - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Valeant Pharmaceuticals International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available